Cargando…
Reverting doxorubicin resistance in colon cancer by targeting a key signaling protein, steroid receptor coactivator
Although there have been notable improvements in treatments against cancer, further research is required. In colon cancer, nearly all patients eventually experience drug resistance and stop responding to the approved drugs, making treatment difficult. Steroid receptor coactivator (SRC) is an oncogen...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
D.A. Spandidos
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863609/ https://www.ncbi.nlm.nih.gov/pubmed/29581735 http://dx.doi.org/10.3892/etm.2018.5912 |